SCHEMBL4486967

SCHEMBL4486967

CCOC(=O)c1cn(-c2cccc(Br)c2)nc1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 3/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
LMNA P02545 2/20 0.47
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RAB9A P51151 3/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298281 0.88 DGAT1 (0.66) DGAT1SMN1; SMN2NPC1ALDH1A1POLB
SCHEMBL443532 0.88 DGAT1 (0.52) DGAT1SMN1; SMN2NPC1ALDH1A1POLB
SCHEMBL16691194 0.88 DGAT1 (0.55) DGAT1SMN1; SMN2NPC1ALDH1A1POLB
SCHEMBL24303811 0.86 CA12 (0.56) DGAT1SMN1; SMN2NPC1ALDH1A1LMNA
SCHEMBL408172 0.86 NPSR1 (0.60) DGAT1SMN1; SMN2NPC1ALDH1A1POLB
SCHEMBL4497357 0.83 ALDH1A1 (0.50) SMN1; SMN2NPC1ALDH1A1POLBLMNA
SCHEMBL407229 0.83 DGAT1 (0.45) DGAT1SMN1; SMN2NPC1ALDH1A1LMNA
SCHEMBL18039473 0.82 NPC1 (0.51) SMN1; SMN2NPC1ALDH1A1POLBLMNA
SCHEMBL4486286 0.82 SMN1; SMN2 (0.52) DGAT1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4299394 0.81 DGAT1 (0.61) DGAT1NPC1ALDH1A1MAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589116-B2 Biaryl substituted pyrazoles as sodium channel blockers MERCK & CO. INC. (US) 2009-09-15 US disclosed
EP-1615895-A4 BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS MERCK & CO INC (US) 2007-11-07 EP disclosed
US-20060183785-A1 Biaryl substituted pyrazoles as sodium channel blockers MERCK SHARP & DOHME CORP. 2006-08-17 US disclosed
EP-1615895-A1 BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2006-01-18 EP disclosed
WO-2004092140-A1 BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183785-A1 Biaryl substituted pyrazoles as sodium channel blockers TRPV1, TRPA1, TRPV3 DGAT1 4184/4885SMN1; SMN2 836/4885NPC1 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.